Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review

Aimee Fake1,2,*, Anil Ranchord2,3, Scott Harding2,3 and Peter Larsen1,2

1Department of Surgery & Anaesthesia, University of Otago, Wellington, New Zealand; 2Wellington Cardiovascular Research Group, Wellington, New Zealand; 3Department of Cardiology, Wellington Hospital, Wellington, New Zealand

Abstract: Background: Patients with acute coronary syndromes (ACS) and a history of atrial fibrillation (AF) have indications for both dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC). Triple therapy (TT), the combination of DAPT and OAC, is recommended in guidelines. We examined studies comparing clinical outcomes on DAPT versus TT for patients with AF and ACS.

Methods: We searched Medline, Medline pending, EMBASE and Evidence-Based Medicine Reviews databases for studies published between January 2000 to December 2016 in AF patients with ACS that compared DAPT and TT that reported ischaemic and/or bleeding outcomes. Studies that were not purely an AF population were excluded.

Results: Ten studies were included in the review, all of which were observational, 8 of which were retrospective. None of the studies detailed the specifics of treatment allocation. All but one were of AF patients with a mix of stable coronary disease and ACS patients. TT was associated with increased bleeding when compared to DAPT, with adjusted odds ratios ranging from 1.25 to 6.84. While the largest study reported a reduction in stroke associated with TT (odds ratio 0.67), two other studies reported non-significant increases in stroke with TT. Variable composite ischaemic endpoints were reported, none showing a statistical significant difference between DAPT and TT.

Conclusion: In patients with ACS and AF, TT is likely to be associated with increased risk of bleeding, without a clear reduction in ischaemic endpoints. The quality of the evidence to support current guidelines for this patient group was generally poor.

Keywords: Atrial fibrillation, acute coronary syndrome, triple therapy, dual antiplatelet therapy, systematic literature review.

1. INTRODUCTION

Atrial fibrillation (AF) is the most commonly sustained cardiac arrhythmia and is associated with substantial risk of thromboembolism and mortality [1]. Treatment with an oral anticoagulant (OAC) is considered standard-of-care in patients with AF at moderate to high risk of thromboembolism and is superior to dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for the prevention of ischaemic stroke and systemic embolization [2].

Presentation with acute coronary syndromes (ACS) and concurrent AF is common with studies reporting between 6 and 21% of patients with ACS have concurrent AF [3]. Patients presenting with both ACS and AF tend to be older, have more comorbidities and worse clinical outcomes [4].
2. METHODS

2.1. Search Strategy

We electronically searched Medline, Medline pending, EMBASE and Evidence-Based Medicine Reviews (EBMR) databases, using the MeSH terms “atrial fibrillation” AND “acute coronary syndromes” (all fields), “anticoagulants” OR “platelet aggregation inhibitors” (all fields), and the key words “OAC”, “NOAC”, “Warfarin”, “Apixaban”, “Rivaroxaban”, “Dabigatran”, “Darexaban”, “triple therapy” “dual antiplatelet therapy”, “Clopidogrel”, “Prasugrel”, Ticagrelor” and “antiplatelet” in all fields. Results were limited to English language and human populations. In addition, the reference lists of pertinent articles were manually screened for eligible articles. We limited the search strategy to results from 1st January 2000 to 31st December 2016.

2.2. Inclusion Criteria

Studies had to meet all of the following criteria: (1) AF patients with an ACS or coronary artery disease undergoing intervention; (2) comparison of DAPT and TT; (3) inclusion of either ischaemic and/or bleeding outcomes. Studies that were based on mixed populations on anticoagulant therapy that were not purely an AF population were excluded. Where more than one study reported on the same patient population only the most recent report was included.

2.3. Data Extraction

Abstracts were screened to assess eligibility. The full text article was examined for all potentially eligible studies.

3. RESULTS

The search strategy identified 1888 titles. After the removal of duplicates 1599 abstracts were screened. A final set of 10 papers met the inclusion criteria (see Fig. 1) and details of these are given in Table 1. Where author groups published more than one study from largely the same patient population (Sambola et al. [9, 10], Lamberts et al. [11, 12] & Fosbol et al. [13, 14]) only the most recent study was included in the current review. There was considerable heterogeneity between studies with respect to outcomes, patient numbers in the DAPT and TT arms (range n=67 to n=5486) and follow-up periods (6 months - 42 months). Of the 10 studies, only Sambola et al. (2016) [9] and Rubboli et al. (2014) [15] were prospective in nature.

The proportion of patients with an ACS ranged from 40% in Suh et al. (2014) [16] to 100% in Fosbol et al. (2013) [13]. In 6 of the 10 studies the proportion of patients with ACS was higher in the DAPT treatment arm than in the TT arm. Details of paroxysmal, persistent and permanent AF groups could not be determined and in all cases the term AF was used to collectively represent these groups. Allocation to
DAPT or TT was at the discretion of the physician in 6 studies and not described in the remaining 4 studies (Table 1). When treatment was physician determined there were no reports of institutional protocols or schema to assist physician decision making. Nine studies had a follow up duration greater than or equal to 12 months and in these studies there were no statements regarding the duration of either DAPT or TT, or what therapy was adopted once DAPT or TT was discontinued.

4. COMPOSITE ISCHAEMIC OUTCOMES

While it was common to report on a composite endpoint, the components of this endpoint differed across the 10 studies. In 7 studies adjusted composite endpoint results were given (Table 2). No individual study found a significant difference in composite end points between groups, although in 4 of the 7 studies there was a trend towards lower rates on TT (odds ratios ranged from 0.71 to 0.94) [11, 13, 17, 18].

5. MORTALITY

While all studies reported unadjusted mortality only three studies reported adjusted results for mortality (Table 2). In Mennuni et al. there was 8.6% 12 month mortality in the DAPT arm compared to a 7.1% rate on TT with an adjusted odds ratio of 0.62 [0.35-1.08] [18]. In Lamberts et al. the 12 month mortality rates for the DAPT and TT arms were 12% and 4% respectively, with adjusted all-cause mortality reduced with TT (OR 0.61 [0.47-0.77]) [11]. Ho et al. reported a 6.8% mortality on DAPT compared to 6.5% on TT, with an adjusted OR 0.96 [0.49-1.86] [17].

Table 1. Overview of included studies.

| Study              | Follow-up     | Population    | Design     | Data Source       | Groups        | Allocation       |
|--------------------|---------------|---------------|------------|-------------------|---------------|------------------|
| Sambola et al.     | 12 months     | AF + PCI      | Prospective| Hospital database | DAPT (n=266)  | Physician alloted|
|                    |               |               |            |                   | TT (n=319)    |                  |
| De Vecchis et al.  | 378 ± 15.9 days| AF + PCI      | Retrospective| Hospital database | DAPT (n=19)   | Physician alloted|
|                    |               |               |            |                   | TT (n=48)     |                  |
| Kang et al.        | 20.6 ± 7.4 months| AF + DES     | Retrospective| Hospital database | DAPT (n=236)  | Physician alloted|
|                    |               |               |            |                   | TT (n=131)    |                  |
| Mennuni et al.     | 12 months     | AF + PCI      | Retrospective| Hospital databases | DAPT (n=488)  | Physician alloted|
|                    |               |               |            |                   | TT (n=371)    |                  |
| Rubboli et al.     | 12 months     | AF + PCI      | Prospective| Hospital databases | DAPT (n=162)  | Physician alloted|
|                    |               |               |            |                   | TT (n=679)    |                  |
| Suh et al.         | 42.0 ± 29.0 months| AF + PCI     | Retrospective| Medical centre database | DAPT (n=166)  | Physician alloted|
|                    |               |               |            |                   | TT (n=37)     |                  |
| Fosbol et al.      | 12 months     | AF + NSTEMI with PCI| Retrospective| CRUSADE registry and insurance database | DAPT (n=1200) | Not stated       |
|                    |               |               |            |                   | TT (n=448)    |                  |
| Lamberts et al.    | 12 months     | AF + MI and/or PCI | Retrospective| Not stated       | DAPT (n=3590) | Not stated       |
|                    |               |               |            |                   | TT (n=1896)   |                  |
| Ho et al.          | 5.9 ± 5.0 months| AF + PCI      | Retrospective| Not stated       | DAPT (n=220)  | Not stated       |
|                    |               |               |            |                   | TT (n=382)    |                  |
| Maegdefessel et al.| 16.8 (2-68) months| AF + PCI   | Retrospective| Hospital database | DAPT (n=103)  | Not stated       |
|                    |               |               |            |                   | TT (n=14)     |                  |

Length of follow up is in months ± standard deviation or months (range); AF = atrial fibrillation; DAPT = dual antiplatelet therapy; DES = drug eluting stent; MI = myocardial infarction; NSTEMI = non ST elevation myocardial infarction; PCI = percutaneous coronary intervention; TT = triple therapy.
**Addition**. Kang *et al.* reported propensity-score matched results and found a 3% mortality rate in the DAPT group compared to 7% in the TT group [19]. In the remaining studies Fosbol *et al.* reported mortality of 13.3% on DAPT versus 12.9% on TT without adjusted results being given [13], Suh *et al.* reported 11.4% mortality on DAPT, with no deaths in the 37 patients treated with TT [16], and Rubboli *et al.* reported 11% mortality rates in both groups [15]. Sambola *et al.* reported no difference in mortality with DAPT and TT arms with respect to patients with a CHA2DS2-VASc of 1 (5.5% versus 7.4%, respectively) and those with CHA2DS2-VASc of 2 or more (10.6% versus 9.2%, respectively) [9]. DeVecchis *et al.* reported 5 all-cause deaths, 1 in the DAPT group and 4 in the TT group [20] and Maegdefessel *et al.* reported 4 cardiovascular deaths, 3 in the DAPT group and 1 in the TT group [21].

### 6. STROKE

All 10 studies reported unadjusted stroke rates and these are given in Table 3. Stroke risk information (using CHADS2 [22] or CHA2DS2-VASc [23]) were given in 8 of these studies. In 2 of the studies the TT group had higher stroke risk than the DAPT group (Mennuni *et al.* CHADS2 scores 2.9 versus 2.5, p<0.01 [18]; Ho *et al.* CHADS2 score 2.6 vs. 2.1, p<0.001 [17]), while in one the DAPT group had a higher stroke risk (Kang *et al.* CHADS2 scores 2.06 vs. 1.68, p=0.003) [19]. In the studies by Suh *et al.* [16], Rubboli *et al.* [15] and Fosbol *et al.* [13] the TT and DAPT groups had no statistical difference in their stroke risk. Lamberts *et al.* [11] and Sambola *et al.* [9] did not report statistical comparison of stroke risks between treatment arms, but data given appear similar.

DeVecchis *et al.* did not report stroke risk for the DAPT and TT arms, but reported 1 stroke event (2%) in the 48 patients in the TT arm and no strokes in the 19 patients in the DAPT arm [20]. Maegdefessel *et al.* also did not report stroke risk, and reported the highest stroke rate in the DAPT arm (8.7%), and reported no stroke in the 14 patients treated with TT [21].

In the other 8 studies the stroke rate varied between 0.2 and 5.3%. Of the 7 studies that performed statistical analyses only Sambola *et al.* reported significantly different stroke rates based on unadjusted results, with 5.3% in the DAPT group and 1.7% in the TT group (p=0.03) [9, 13, 15-19].

Three studies presented adjusted results for stroke, with variable findings (see Table 2). Lamberts *et al.* reported that TT significantly reduced the risk of stroke compared to DAPT (OR 0.67, 0.46-0.98) [11]. Both Mennuni and Ho reported results favouring DAPT (OR 4.4 [0.45-42.3] [18] and OR 1.15 [0.21-6.35] [17] respectively), however neither of these results were statistically significant. In addition Kang *et al.* presented propensity-score matched stroke results, reporting no strokes in the DAPT group and 4% in the TT group [19].

### 7. BLEEDING

Different definitions of bleeding were used across the 10 studies (Table 4), and this resulted in differing rates of bleeding observed from a low of no bleeding to a high of 16.7% bleeding. Bleeding risk, using either HAS-BLED [24] or ATRIA [25] scores were reported in 7 of the 10 studies. In 5 of these studies there was no statistical difference in bleeding risk between treatment arms [13, 15, 16, 18, 19]. Lamberts *et al.* [11] and Sambola *et al.* [9] did not perform statistical

---

**Table 2.** Adjusted outcomes.

| Study                  | DAPT Patients | TT Patients | Composite Endpoint                                                                 | OR Composite | OR Mortality | OR Stroke | OR Bleeding |
|------------------------|---------------|-------------|-------------------------------------------------------------------------------------|--------------|--------------|-----------|-------------|
| Sambola *et al.* (2016) [9] | N=266, 79% ACS | N=319, 68% ACS | Mortality, MI, stent thrombosis, repeat revascularisation                           | 1.05 (0.67-1.86) | -            | -         | 2.97 (1.25-7.02)** |
| Kang *et al.* (2015) [19]   | N= 99, 73.7% ACS | N= 99, 76.7% ACS | Mortality, MI, repeat revascularisation, stroke                                      | 1.57 (0.82-2.99)† | 3% DAPT vs. 7% TT† | 0% DAPT vs. 4% TT† | 6.84 (1.98-23.6)**† |
| Mennuni *et al.* (2015) [18] | N=488, 57% ACS | N=371, 54% ACS | Mortality, MI, stroke                                                              | 0.77 (0.52-1.14) | 0.62 (0.35-1.08) | 4.4 (0.45-42.3) | 1.79 (1.11-2.89)* |
| Rubboli *et al.* (2014) [15] | N=162, 66% ACS | N=679, 54% ACS | Mortality, MI, stent thrombosis, repeat revascularisation                           | 1.17 (0.57-2.5) | -            | -         | -           |
| Fosbol *et al.* (2013) [13]  | N=1200, 100% ACS | N=448, 100% ACS | Mortality, MI, stroke                                                              | 0.94 (0.73-1.21) | -            | -         | 1.29 (0.96-1.74) |
| Lamberts *et al.* (2013) [11] | N=3590, 72% ACS | N=1896, 53% ACS | MI, Coronary death                                                                | 0.83 (0.68-1.00) | 0.61 (0.47-0.77)* | 0.67 (0.46-0.98)* | 2.08 (1.64-2.65)* |
| Ho *et al.* (2013) [17]     | N=220, 68% ACS | N=382, 71% ACS | Mortality, ischemic stroke, TIA                                                   | 0.71 (0.37-1.38) | 0.96 (0.49-1.86) | 1.15 (0.21-6.35) | 1.25 (0.6-2.6)† |

Odds ratios (OR) are given relative to dual antiplatelet therapy (DAPT). Abbreviations ACS = acute coronary syndrome; MI = myocardial infarction; TIA = transient ischemic attack; TT = triple therapy. Statistical significant results are given by * p < 0.05, ** p < 0.01 *** p < 0.001. †results were propensity-score matched, not adjusted; ‡ Bleeding odds ratio was for the subgroup of patients with a CHADS2 score of greater than 2.
analysis however bleeding risk appears to be similar in both treatment arms.

Unadjusted bleeding rates were presented in all 10 studies and significant differences were observed in 3. Kang et al. reported a 16.7% bleeding rate in the TT group, significantly higher than the 4.6% in the DAPT group [19], and Mennuni et al. reported an 11.5% bleeding rate for TT group compared with 6.4% for DAPT [18]. Sambola et al. [9] also showed higher bleeding in the TT group (8.4%) when compared to the DAPT group (3.1%). Four studies (DeVecchis et al. [20], Rubboli et al. [15], Suh et al. [16] and Ho et al. [17]) did not find significant differences between bleeding rates while three studies (Fosbol et al. [13], Lamberts et al. [11] and Maegdefessel et al. [21]) did not perform statistical analyses on unadjusted bleeding rates.

Adjusted bleeding results were presented in 6 studies (see Table 1) and in 4 of these there was a statistically significant increase in bleeding associated with TT (Sambola et al. OR 2.97 [1.25-7.02], Kang et al. OR 6.84 [1.98-23.6], Lamberts et al. OR 2.08 [1.64-2.65] and Mennuni et al. OR 1.79, [1.11-2.89]). The other two studies reported non-significant increases in bleeding with TT (Fosbol et al. OR 1.29 [0.96-1.74], Ho et al. OR 1.25 [0.6-2.6]).

8. DISCUSSION
The quality of studies identified comparing clinical outcomes for patients with AF and ACS/PCI treated with DAPT or TT was poor. Eight of the ten studies included in this review were retrospective in nature, and none of the studies adequately described the basis of treatment allocation. Only one study was of a pure ACS population, the other nine containing a mix of stable coronary artery disease patients undergoing PCI and ACS patients. There was consistency in the observation that TT was associated with an increase in the rate of bleeding. While the largest study of the ten observed a reduction in stroke and in mortality associated with TT compared to DAPT, this was not a consistent finding.

This systematic review highlights a large gap in current literature, the lack of randomised control trials assessing treatment for patients with AF and ACS. Between 6 – 21% of patients with ACS may have concurrent AF, so this is a common clinical presentation [3]. In addition, a number of studies have shown that patients with AF have worse clinical outcomes following ACS than those without AF [26-28]. The absence of robust data on which to base treatment recommendations is therefore a significant concern. The latest ESC guidelines for NSTEMI-ACS had a number of treat-

### Table 3. Unadjusted stroke rates.

| Study                  | DAPT Patients | DAPT Stroke Risk | DAPT Stroke Rate (%) | TT Patients | TT Stroke Risk | TT Stroke Rate (%) |
|------------------------|---------------|------------------|----------------------|-------------|----------------|--------------------|
| Sambola et al. (2016)  | N=266         | 45% CHA:DS:VASc 2+ | 5.3*                 | N=319       | 56% CHA:DS:VASc 2+ | 1.7                |
| DeVecchis et al. (2016)| N=19          | Not given        | 0                    | N=48        | Not given      | 2                  |
| Kang et al. (2015)    | N=236         | Mean CHADS: 1.68* | 2.1                  | N=131       | Mean CHADS: 2.06 | 3                  |
| Mennuni et al. (2015) | N=488         | Mean CHADS: 2.5*  | 0.2                  | N=371       | Mean CHADS: 2.9  | 1.2                |
| Rubboli et al. (2014) | N=162         | Mean CHADS: 2.1  | 4                    | N=679       | Mean CHADS: 2.3  | 2                  |
| Suh et al. (2014)     | N=166         | 65% CHADS:2+     | 3.6                  | N=37        | 57% CHADS:2+    | 2.7                |
| Fosbol et al. (2013)  | N=1200        | Median CHA:DS:VASc:4 | 2.2           | N=448       | Median CHA:DS:VASc:4 | 1.6           |
| Lamberts et al. (2013)| N=3590        | 90% CHA:DS:VASc 2+ | 4.2†                | N=1896      | 90% CHA:DS:VASc 2+ | 1.8                |
| Ho et al. (2013)      | N=220         | Mean CHADS: 2.1*  | 0.9                  | N=382       | Mean CHADS: 2.6  | 1.1                |
| Maegdefessel et al.   | N=103         | Not given        | 8.7†                 | N=14        | Not given      | 0                  |

ACS = acute coronary syndrome; DAPT= dual antiplatelet therapy; TT = triple therapy. Statistically significant differences between treatment arms are indicated by * p <0.05.† statistical comparison of stroke rates not performed.
ment recommendations for AF and ACS patients that had level of evidence C (expert opinion) [29]. The studies included in this review were all observational, mostly retrospective, and some very small. A number of these studies incorporated treatment groups other than DAPT and TT although these have not been discussed here. The original intent of this review had been to limit the studies discussed to pure ACS-AF populations. However, this would have left only the study by Fosbol et al. included [13]. The change to a mixed ACS and stable coronary disease inclusion expanded the number of studies included, but at the risk of altering the characteristics of the patient population. Treatment allocation was inadequately described in all studies. While consensus documents suggest stratifying patient by risk to determine treatment regimen [4, 7, 29], none of the studies included in this review have stated that this was done. The similarity in stroke and bleeding risk scores between the treatment arms in the majority of studies supports this notion. There are ongoing randomised trials such as REDUAL-PCI (dual therapy with dabigatran and either clopidogrel or ticagrelor, versus TT with warfarin, in patients with AF undergoing PCI) [30] and MUSICA-2 (DAPT vs. TT in patients with AF and low to moderate thromboembolic risk undergoing PCI) [31] which when completed may provide more guidance regarding optimal pharmacological therapy, but none will directly address ACS patients with AF.

On the basis of the small number of studies in this systematic review it is evident that bleeding rates are significantly higher in patients treated with TT compared to DAPT. This was demonstrated consistently in the adjusted results, including the two largest studies, Fosbol et al. [13] and Lamberts et al. [11], with the former particularly pertinent as it was the only study to only include patients with ACS. Greater bleeding in TT groups was also supported in the majority of unadjusted results. There are some limitations that need to be noted here. Bleeding definitions used varied considerably, and the observed bleeding rates varied in part as a consequence of this. However, some of the studies that only included major bleeding reported higher rates of bleeding than others that had broader definitions of bleeding. It is possible that some bleeding was not captured in some of these studies due to the retrospective nature of most of the studies.

The bleeding results reported in this study are consistent with the data from randomised controlled trials conducted in ACS populations that have compared TT to DAPT. In AT-

### Table 4. Unadjusted bleeding rates.

| Study                          | DAPT Patients | DAPT Bleeding Risk | DAPT Bleeding Rate (%) | TT Patients | TT Bleeding Risk | TT Bleeding Rate (%) | Bleeding Definition |
|-------------------------------|---------------|--------------------|------------------------|-------------|-----------------|----------------------|---------------------|
| Sambola et al. (2016) [9]     | N=266         | HASBLED ≥3, 37%    | 3.1*                   | N=319       | HASBLED ≥3, 42% | 8.4                  | TIMI Major           |
| DeVecchis et al. (2016) [20]  | N=19          | Not given          | 5.3                    | N=48        | Not given       | 8.3                  | Major bleeding – not defined |
| Kang et al. (2015) [19]       | N=236, 77.4%  | HASBLED, mean 2.1 | 4.6*                   | N=131, 77.8% | HASBLED, mean 2.2 | 16.7                 | Intracerebral or hemodynamic compromise |
| Mennuni et al. (2015) [18]    | N=488, 57%    | HASBLED, mean 2.9 | 6.4*                   | N=371, 54%  | HASBLED, mean 2.9 | 11.5                 | BARC 2+              |
| Rabboli et al. (2014) [15]    | N=162, 66%    | HASBLED, mean 2.9 | 12                     | N=679, 54%  | HASBLED, mean 2.9 | 10                   | BARC3 & 5            |
| Sub et al. (2014) [16]        | N=166, 42%    | HASBLED, mean 2.0 | 0.6                    | N=37, 33%   | HASBLED, mean 1.9 | 2.7                  | Overt bleeding, need for transfusion, intracranial bleeding |
| Fosbol et al. (2013) [13]     | N=1200, 100%  | ATRIA, median 3   | 11.9†                  | N=448, 100% | ATRIA, median 3  | 14.4                 | Bleeding causing hospital admission |
| Lamberts et al. (2013) [11]   | N=3590, 72%   | HASBLED ≥3, 24.3% | 4.6†                   | N=1896, 53% | HASBLED ≥3, 24.3% | 6.2                  | Bleeding causing hospital admission or death |
| Ho et al. (2013) [17]         | N=220, 68%    | No bleeding risk score | 9.6                    | N=382, 71%  | No bleeding risk score | 10.6                 | Bleeding requiring transfusion |
| Maegdefessel et al. (2008) [21]| N=103, 89%    | No bleeding risk score | 1.9†                   | N=14, 72%   | No bleeding risk score | 0                   | Not defined in methods – requiring transfusion stated in results |

ACS = acute coronary syndrome; BARC = Bleeding academic research consortium [48]; DAPT = dual antiplatelet therapy; TT = triple therapy. Statistically significant differences between treatment arms are indicated by *p < 0.05† statistical comparison of stroke rates not performed.
LAS ACS 2-TIMI-51 patients were randomised to rivaroxaban low dose (2.5mg twice daily) or high dose (5mg twice daily) plus DAPT or DAPT alone [32]. This study reported a reduction in cardiovascular and all-cause mortality associated with the low dose of rivaroxaban (but not the higher dose) and an increase in non-CABG related major bleeding but not fatal bleeding in both TT groups. The APPRAISE-2 study examined the addition of apixaban (5mg twice daily) to DAPT. This study was halted prematurely as there was no evidence of a reduction in the composite end point of cardiovascular death, MI or ischaemic stroke associated with TT, and a significant increase in major bleeding was observed in the apixaban group [33]. A recent meta-analysis including the two phase III trials APPRIASE-2 and ATLAS ACS2-TIMI 51 and 5 phase II trials in ACS with DAPT and TT arms reported an increased risk of bleeding associated with TT (Hazard Ratio 2.34; 2.06-2.66) with a modest reduction in MACE (HR 0.87;0.80-0.95 ) [34]. A similar association was described in a sub-study of the RE-LY trial, demonstrating that for warfarin and both 110mg and 150mg doses of dabigatran, addition of antiplatelet agents resulted in increased major bleeding [35]. Furthermore, nationwide registry data from Denmark of 40,812 MI patients showed that risk of bleeding causing hospitalisation increased with the number of antithrombotic drugs used, with those on TT at highest risk (compared to aspirin, DAPT HR 1.47 (1.28-1.69), TT HR 4.05 (3.08-5.33) [36]. Taking the results from these studies together with the findings in this review, it seems highly likely that TT in AF and ACS patients will result in an increase in clinically important bleeding.

The efficacy of TT was less clear in the studies reviewed here. It might have been expected that the major benefit of TT would be seen in a reduction in the rate of stroke. This is based on meta-analysis of AF studies, showing superiority of warfarin to antiplatelet therapy for the reduction in stroke [37]. Consistent with this, the largest study included in this review did observe a reduction in stroke associated with TT [11]. However the second largest study, Fosbol et al. reported a 2.2% rate of stroke on DAPT and a 1.6% rate on TT, which were not significantly different in unadjusted analysis. Three other studies reported a trend towards higher stroke rates on TT in adjusted analysis, although in none of these cases was a statistically significant result observed [17-19]. These results suggest that the benefits of adding warfarin to DAPT for stroke prevention in the context of ACS in AF patients is not clear.

It is also unclear that there is a reduction in composite ischaemic endpoints or in mortality associated with TT, although in the case of mortality Lamberts et al. did demonstrate a mortality advantage [11]. Whilst it is conceivable that addition of and OAC to DAPT may reduce mortality related to thromboembolic events [32], it is also clear that major bleeding events in patients with ACS are associated with an increase in mortality [38, 39].

The ESC AF guidelines of 2014 [8] include a structured algorithm based on stroke risk and bleeding risk to determine the combination of antithrombotic and antiplatelet therapy. The subsequent ESC NSTEM-ACS guidelines of 2015 [29] present a simplified version that does recommend TT for all ACS patients undergoing PCI, for 1 month in those with high bleeding risks and 6 months for those with lower bleeding risk, followed by dual therapy (clopidogrel and anticoagulation) out to 12 months. Bleeding risk in this context is defined by HASBLED[24], and while this score has been well validated in AF, it has not been validated in AF and ACS. The current ACC/AHA STEMI [40] and NSTEMI [41] guidelines both note the increased risk of bleeding associated with TT, and suggest that where this is warranted, an INR of 2.0 to 2.5 might be considered. The ACC/AHA guidelines do not reference a bleeding score. The studies included in the current review showed similar bleeding scores in both treatment arms suggesting that bleeding risk was not strongly associated with treatment allocation. In three studies there was a higher stroke risk in the TT arm, which may indicate stroke risk was a factor in treatment allocation in at least some cases.

Within the ESC guidelines [8, 29] the term OAC is used and refers to either well-controlled warfarin or one of the novel oral anticoagulants. It is important to note that all of the studies in this review that used oral anticoagulants were using dabigatran, prasugrel and ticagrelor, based on no proven benefit in the AF and ACS population. Both prasugrel and ticagrelor have been shown to be superior to clopidogrel on the basis that data is lacking for the newer agents [40]. With regard to DAPT therapy all of the studies in this review are referring to an aspirin and clopidogrel combination. The ESC guidelines advocate the use of aspirin and clopidogrel to constitute DAPT in the context of AF, but not the newer P2Y12 receptor inhibitors prasugrel and ticagrelor. This review has focused exclusively on the comparison of DAPT and TT. However, the combination of OAC and a single antiplatelet agent for AF and ACS patients may be important to consider. Lamberts et al. included both aspirin and warfarin, and aspirin and clopidogrel treatment arms in their study, and found both resulted in significantly less bleeding than TT, without any difference in rates of stroke [11]. The WOEST trial, examined OAC + antiplatelet (VKA + clopidogrel) to TT (VKA + clopidogrel + aspirin) in a slightly different population (69% AF and only 25-30% ACS). At 1 year follow-up significantly less total bleeding occurred in the oral anticoagulant plus clopidogrel group (HR 0.36, [0.26-0.50], p<0.0001), with no difference in major bleeding detectable. This reduction in bleeding was accompanied with a decreased rate of thrombotic events (com-
posite of MI, stroke, TVR and stent thrombosis) (HR 0.6, [0.38-0.94], p=0.025), and showed an all-cause mortality benefit over TT (HR 0.39, [0.16-0.93], p=0.027) [48]. The recently completed PIONEER AF-PCI study examined dual therapy (rivaroxaban and P2Y12 inhibitor), versus TT with rivaroxaban or warfarin, in AF patients undergoing PCI, with about 50% of the patients having ACS. There was no DAPT arm in this study, so the study did not meet the inclusion criteria for our systematic review. The warfarin, aspirin, P2Y12 inhibitor arm of this study had the highest bleeding rate, and the lowest bleeding rate was observed in the rivaroxaban-clopidogrel arm. The study was not powered to examine efficacy, and no difference in MACE between groups was reported [49]. While it is possible that some combination of novel OAC and a single antiplatelet agent may be superior to DAPT or TT, this is not currently recommended therapy within guidelines. Examining the utility of an oral anticoagulant and a single antiplatelet agent may therefore have merit. This area is now considerably more complex, as the novel oral anticoagulants and new antiplatelet drugs provide an increased range of possible therapeutic combinations, at a range of dosing options, that adds to the confusion in how best to treat AF patients with ACS.

9. STUDY LIMITATIONS

We excluded a number of studies that were based on populations on oral anticoagulant treatment at the time of an ACS event. These studies would have included mostly AF patients, mixed with a smaller proportion of patients with mechanical valves, DVT/PE or other indications for anticoagulation. Our rationale for this exclusion was that the non-AF patients included have quite a different risk profile, and that many patients with AF and ACS may not have been on an anticoagulant at the time of the ACS. We did choose to include studies that were not in pure ACS patients, as had we not done so, only one study would have been included in the review. Meta-analyses were not performed due to heterogeneity of eligible studies and absence of randomised control trials. Information regarding the duration of either DAPT or TT, or what default therapy was once DAPT or TT was discontinued was inadequately described in all studies; therefore we were unable to draw inferences about optimal duration of therapy on the basis of our results.

CONCLUSION

Optimal drug therapy in patients with AF and ACS is complex as both atherothrombotic and thromboembolic protection is required. The existing literature comparing DAPT to TT for this group of patients was poor in quality, consisting predominantly of retrospective studies with mixed ACS and PCI patients. There was a lack of detail on treatment allocation, and important differences in the clinical characteristics of DAPT and TT treatment arms were often not accounted for. Where adjusted results were presented, TT was consistently associated with an increase in bleeding risk, but there was not consistent evidence of reduced stroke, or reduced composite ischaemic endpoints associated with TT. This review has highlighted the need for prospective randomised control trials to define optimal therapy and improve outcomes in the AF and ACS population.

CONSENT FOR PUBLICATION

Not applicable.

CONFICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 1. Am J Cardiol 1998; 82: 2N-9.
[2] Connolly S, Yusuf S, Camm J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): A randomised controlled trial. The Lancet 2006; 367: 1903-12.
[3] Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038-45.
[4] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/Cardiology-American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-e76.
[5] Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726-32.
[6] Rubboli A, Milandri M, Castelveci C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Cardiology 2005; 104: 101-6.
[7] Faxon DP, Eikelboom JW, Berger PB, et al. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-84.
[8] Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on ….. Eur Heart J 2014; 35: 3155-70.
[9] Sambola A, Mutuberría M, del Blanco BG, et al. Effects of triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification. Cire J 2016; 80: 354-62.
[10] Sambola A, Mutuberría M, del Blanco BG, et al. Impact of triple therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention: PLoS One 2016; 11: e0147245.
[11] Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62: 981-9.
[12] Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126(10): 1185-93.
[13] Fosbol EL, Wang TY, Li S, et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J 2013; 166: 864-70.
[14] Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J 2012; 163: 720-8.
Triple Therapy Versus Dual Antiplatelet Therapy for Patients

[15] Rubboli A, Schlitt A, Kiviniemi T, et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: An analysis of the AFCAS registry. Clin Cardiol 2014; 37: 357-64.

[16] Suh S, Kang W, Oh P, et al. Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Heart Vessels 2014; 29: 578-83.

[17] Ho KW, Ivanov J, Freixa X, et al. Anti thrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation. Can J Cardiol 2013; 29: 213-8.

[18] Mennuni MG, Halperin JL, Bansilal S, et al. Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention (from the AVIATOR Registry). Am J Cardiol 2015; 116(1): 37-42.

[19] Kang DO, Yu CW, Kim HD, et al. Triple anti thrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. Coron Artery Dis 2015; 26(5): 372-80.

[20] De Vecchis R, Cantatrine C, Mazzei D. Clinical relevance of anticoagulation and dual antiplatelet therapy to the outcomes of patients with atrial fibrillation and recent percutaneous coronary intervention with stent. J Clin Med Res 2016; 8: 153.

[21] Maegdfessell L, Schlitt A, Faerber J, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. Med Clin 2008; 103: 628-32.

[22] Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-92.

[23] Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.

[24] Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest 2010; 138: 1093-100.

[25] Fang MC, Gao AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395-401.

[26] Lopes RD, Li L, Granger CB, et al. Atrial fibrillation and acute myocardial infarction: Anti thrombotic therapy and outcomes. Am J Med 2012; 125: 897-905.

[27] Ruff CT, Bhatt DL, Steg PG, et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol 2014; 170: 413-8.

[28] Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Int Med 2003; 163: 2345-53.

[29] Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2015; 2015: eho320.

[30] Ingelheim B. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL PCI). NLM Identifier: NCT02164864. 2014.

[31] Sambola A, Montoro JB, del Blanco BG, et al. Dual anti platelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial. Am Heart J 2013; 166: 669-75.

[32] Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.

[33] Alexander JH, Lopes RD, James S, et al. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011; 365: 699-708.

[34] Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: A systematic review and meta-analysis. Eur Heart J 2013; 2013: eht049.

[35] Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY®) trial. Circulation 2013; 127(5): 634-40.

[36] Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-74.

[37] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antagonistic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.

[38] Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-82.

[39] Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-66.

[40] O’Gara PT, Kushner FG, Asheim DD, et al. 2013 ACC/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2013; 61: e78-140.

[41] Jneid H, Anderson JI, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-81.

[42] Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a real world/atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584.

[43] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.

[44] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.

[45] Patel MRMD, Mahafey KWMD, Garg JMS, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.

[46] Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.

[47] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.

[48] Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-15.

[49] Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423-34.